Scroll down to choose your session!
Wednesday, June 23 at 6 PM CST.
Endometriosis and Elagolix, indicated for moderate to severe endometriosis pain.
One of the most common gynecologic disorders in the U.S., and affecting roughly 10% (190 million) of reproductive age women and girls worldwide, endometriosis is a highly estrogen-dependent, chronic, inflammatory disease characterized by the growth of endometrial tissue (similar to the lining of the uterus) outside the uterus, causing pain and/or infertility. ORILISSA (Elagolix)represents the first FDA-approved gonadotropin releasing hormone receptor antagonist in the market, and oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade.
This presentation will provide a brief overview of endometriosis disease state, and clinical trial data for Elagolix, indicated for moderate to severe endometriosis pain (FDA approved July 2018). https://www.rxabbvie.com/pdf/orilissa_pi.pdf
Thursday, June 24 at 6 PM CST.
UTERINE FIBROIDS & Elagolix+Estradiol/NETA, indicated for heavy menstrual bleeding associated with uterine leiomyomas in pre-menopausal women
Uterine fibroids, also called leiomyomas, are estrogen and progesterone-dependent non-cancerous tumors of the uterus and are the most common type of benign tumor in women of reproductive age. Traditionally, uterine fibroids have been primarily managed by surgery and are the leading reason for the hysterectomies performed in the U.S. ORIAHNN (Elagolix+Estradiol/NETA) is the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
This presentation will provide a brief scientific overview of disease state and clinical trial data for Elagolix+E2/NETA, indicated for heavy menstrual bleeding associated with fibroids (FDA approved May 2020). https://www.rxabbvie.com/pdf/oriahnn_pi.pdf
Registration deadline has been extended!
Registration Code: 1052
This ballot has closed.